New patient data surrounding Retatrutide , specifically the high-dose formulation referred to as ZPHC, reveal a significant effect on body mass decrease and linked chronic conditions . Scientists posit that this combined acting , affecting both GLP-1 and GIP receptors , could offer a major advance in the approach of excess weight and associated me